Apotransferrin decreases the response of oligodendrocyte progenitors to PDGF and inhibits the progression of the cell cycle.
In the CNS, transferrin (Tf) is expressed by the oligodendroglial cells (OLGcs) and is essential for their development. We have previously shown that apotransferrin (aTf) accelerates maturation of OLGcs in vivo as well as in vitro. The mechanisms involved in this action appear to be complex and have not been completely elucidated. The aim of this study was to investigate if Tf participates in the regulation of the cell cycle of oligodendroglial progenitor cells (OPcs). Primary cultures of OPcs were treated with aTf and/or with different combinations of mitogenic factors. Cell cycle progression was studied by BrdU incorporation, flow cytometry and by the expression of cell cycle regulatory proteins. Apotransferrin decreased the number of BrdU+ cells, increasing the cell cycle time and decreasing the number of cells in S phase. The cell cycle inhibitors p27kip1, p21cip1 and p53 were increased, and in agreement with these results, the activity of the complexes involved in G1-S progression (cyclin D/CDK4, cyclin E/CDK2), was dramatically decreased. Apotransferrin also inhibited the mitogenic effects of PDGF and PDGF/IGF on OPcs, but did not affect their proliferation rate in the presence of bFGF, bFGF/PDGF or bFGF/IGF. Our results indicate that inhibition of the progression of the cell cycle of OPcs by aTf, even in the presence of PDGF, leads to an early beginning of the differentiation program, evaluated by different maturation markers (O4, GC and MBP) and by morphological criteria. The modulation by aTf of the response of OPcs to PDGF supports the idea that this glycoprotein might act as a key regulator of the OLGc lineage progression.
Paez
P M
PM
Instituto de Química y Fisicoquímica Biológica (IQUIFIB), UBA-CONICET, and Departamento de Química Biológica, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Junin 956, Buenos Aires C1113AAD, Argentina.
Garcia
C I
CI
Soto
E F
EF
Pasquini
J M
JM
D000818:Animals; D000963:Antimetabolites; D001059:Apoproteins / Q000494:pharmacology*; D015153:Blotting, Western; D001973:Bromodeoxyuridine; D002453:Cell Cycle / Q000187:drug effects*; D002454:Cell Differentiation / Q000187:drug effects; D018844:Cyclin-Dependent Kinases / Q000378:metabolism; D004247:DNA / Q000096:biosynthesis; D003864:Depression, Chemical; D004591:Electrophoresis, Polyacrylamide Gel; D005434:Flow Cytometry; D016193:G1 Phase; D007150:Immunohistochemistry; D009836:Oligodendroglia / Q000187:drug effects* / Q000648:ultrastructure; D010982:Platelet-Derived Growth Factor / Q000037:antagonists & inhibitors* / Q000494:pharmacology*; D051381:Rats; D016196:S Phase; D013234:Stem Cells / Q000187:drug effects* / Q000648:ultrastructure; D013778:Tetrazolium Salts; D013844:Thiazoles; D014168:Transferrin / Q000494:pharmacology*
D000963:Antimetabolites; D001059:Apoproteins; D010982:Platelet-Derived Growth Factor; D013778:Tetrazolium Salts; D013844:Thiazoles; D014168:Transferrin; C028284:apotransferrin; D004247:DNA; D018844:Cyclin-Dependent Kinases; C022616:thiazolyl blue; D001973:Bromodeoxyuridine